Page 57 - 《中国药房》2025年5期
P. 57
新型环状单羰姜黄素类似物的合成及其抗乳腺癌活性研究
Δ
1
1 #
1*
2
1
冯先虎 ,陈泳洁 ,陈 林 ,侯 益 ,曹婉君 ,苏 强 (1.首都医科大学附属北京安贞医院南充医院·南充市
1
中心医院药学部,四川 南充 637500;2.中江县人民医院临床药学科,四川 德阳 618100)
中图分类号 R914;R965 文献标志码 A 文章编号 1001-0408(2025)05-0563-05
DOI 10.6039/j.issn.1001-0408.2025.05.10
摘 要 目的 设计并合成单羰基姜黄素类似物,并考察其抗乳腺癌活性。方法 通过羟醛缩合反应获得单羰基姜黄素类似物
F1、F2和F3,采用MTT法检测其抗肿瘤(包括人乳腺癌细胞MCF-7和人肺癌细胞A549)活性[以半数抑制浓度(IC50 )评估],并与姜
黄素进行比较。根据生物信息学分析方法分别获取F1、F2和F3作用于乳腺癌的第一核心蛋白,并进行分子对接验证。采用细胞
实验进一步考察高、中、低浓度(16、8、4 μmol/L)的F1、F2和F3对MCF-7细胞中对应第一核心蛋白以及中浓度的F1、F2和F3对细
胞中剪切型胱天蛋白酶 3(cleaved-caspase-3)表达的影响。结果 与姜黄素相比,F1、F2 和 F3 对 A549、MCF-7 细胞的 IC50 (F2 对
A549 细胞的 IC50除外)均显著降低(P<0.05 或 P<0.01),其中 F2 对 MCF-7 细胞的 IC50最小,为(9.67±1.27)μmol/L。生物信息学
分析结果显示,F1、F2 和 F3 与其对应第一核心蛋白表皮生长因子受体(EGFR)、蛋白激酶 B(AKT)、AKT 的亲和力指数分别为
5.909 2、8.402 5和6.486 6。高浓度的F1可显著降低MCF-7细胞中EGFR蛋白磷酸化水平(P<0.01),低、中、高浓度的F2和高浓
度的F3均可显著降低MCF-7细胞中AKT蛋白磷酸化水平(P<0.05或P<0.01),中浓度的F1、F2、F3均可显著升高MCF-7细胞中
cleaved-caspase-3蛋白表达水平(P<0.01)。结论 设计合成的单羰基姜黄素类似物F1、F2、F3均具有良好的抗乳腺癌活性,其中
F2的抗乳腺癌活性更好。
关键词 姜黄素;单羰基姜黄素类似物;乳腺癌;羟醛缩合反应;生物信息学;分子对接;细胞凋亡
Synthesis and anti-breast cancer activity of novel cyclic mono-carbonyl curcumin analogues
2
1
1
FENG Xianhu ,CHEN Yongjie ,CHEN Lin ,HOU Yi ,CAO Wanjun ,SU Qiang(1. Dept. of Pharmacy, Beijing
1
1
1
Anzhen Nanchong Hospital, Capital Medical University & Nanchong Central Hospital, Sichuan Nanchong
637500, China;2. Dept. of Clinical Pharmacy, Zhongjiang County People’s Hospital, Sichuan Deyang 618100,
China)
ABSTRACT OBJECTIVE To design and synthesize mono-carbonyl curcumin analogues(MCACs) and investigate the activities
of them against breast cancer. METHODS The analogues F1, F2, and F3 were obtained by aldol condensation reaction, and their
antitumor activities(including the activities of human breast cancer cell MCF-7 and human lung cancer cell A549) were detected by
MTT assay [evaluated with half inhibitory concentration(IC50 )]. The results of MTT assay were compared with those of curcumin.
Bioinformatics methods were used to collect the core targets of analogues F1, F2 and F3 acting on breast cancer, and then
molecular docking verification was carried out. The cell experiments were conducted to investigate the effects of high, medium and
low concentrations (16, 8, 4 μmol/L) of F1, F2 and F3 on the expression of the first core target protein as well as the effects of
medium concentration of F1, F2 and F3 on the expression of cleaved-caspase-3. RESULTS Compared with curcumin, IC50 of
analogues F1, F2 and F3 to A549 and MCF-7 cells(except for IC50 of analogue F2 to A549 cells) were decreased significantly(P<
0.05 or P<0.01); among them, IC50 of analogue F2 to MCF-7 cell was the lowest, being(9.67±1.27) μmol/L. Bioinformatics
analysis showed that index of affinity of analogues F1, F2 and F3 with the first core target epidermal growth factor receptor
(EGFR), protein kinase B (AKT) and AKT were 5.909 2, 8.402 5 and 6.486 6, respectively; high concentration of F1 could
significantly reduce the phosphorylation level of EGFR protein in MCF-7 cells(P<0.01), while low, medium, and high
concentrations of F2 and high concentration of F3 could significantly reduce the phosphorylation level of AKT protein in MCF-7
cells(P<0.05 or P<0.01). Medium concentration of F1, F2, and F3 could significantly increase the expression level of cleaved-
caspase-3 protein in MCF-7 cells(P<0.01). CONCLUSIONS Designed and synthesized MCACs F1, F2 and F3 all have good anti-
breast cancer activity, and F2 has better anti-breast cancer activity.
KEYWORDS curcumin; mono-carbonyl curcumin analogues; breast cancer; aldol condensation reaction; bioinformatics;
molecular docking; cell apoptosis
Δ 基金项目 四川省自然科学基金项目(No.2022NSFSC0711);南
充市科技项目(市校科技战略合作专项)(No.22SXQT0166) 乳腺癌是一个全球性的健康问题,也是癌症死亡的
*第一作者 药师,硕士。研究方向:创新药物研究与制剂开发。
[1]
主要原因之一 。当前,乳腺癌的治疗方式除了早期手
E-mail:15283826125@163.com
[2]
术切除外,化疗依然是其主要治疗方式 。然而传统化
# 通信作者 主任药师,硕士生导师。研究方向:抗肿瘤药物的耐
药机制。E-mail:187169442@qq.com 疗药物在乳腺癌治疗过程中,仍然面临着不良反应严重
中国药房 2025年第36卷第5期 China Pharmacy 2025 Vol. 36 No. 5 · 563 ·